BOSTON, Jan. 19, 2021 /PRNewswire/ -- The leader in site specific bioconjugation and DAR (drug to antibody ratio) optimization in antibod...
EMPOWERING
PROTEIN ENGINEERING FOR NEXT GENERATION BIOLOGICS
Site-specific, homogeneous modification of proteins through unique genetic code expansion platform
UNIQUE BIOCONJUGATION PLATFORM
BrickBio's platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective modifications for research and therapeutic applications and enables novel classes of biologics, including multi-site bispecific antibodies.
OUR
TECHNOLOGY
PROTEIN ENGINEERING
Improve protein characteristics, such as increasing serum half-life, improved specificity, or boosted activity
BIOCONJUGATION KITS
RUO kits are available for a variety of applications: dye-linked, oligo-linked,
and immuno-based assays
PHARMA PARTNERSHIPS
Development of custom protein-based therapeutics or research assays to drastically improve R&D productivity
ANTIBODY CONJUGATION
Empowering the next generation of ADCs with improved efficacy, dosage, and modification homogeneity
THERAPEUTIC PIPELINE
We are currently developing early-stage biologic therapeutic candidates with improved characteristics
IN VIVO CELL BASED ASSAYS
Investigation of protein half-life or protein-protein interactions in vivo with high temporal control
RECENT NEWS
BOSTON, Jan. 6, 2021 /PRNewswire/ -- BrickBio, the leading company in site-specific bioconjugation for improved therapeutics, has signed ...
The company is developing biologics across three internal programs BOSTON, Nov. 10, 2020 /PRNewswire/ -- The leading company in site-spec...
Therapeutic Pipeline
OUR TEAM
CEO, Co-Founder,
TIGER GENE
VP, COMMERCIAL
DEVELOPMENT
SENIOR ADVISOR &
CHAIRMAN OF SAB
HEAD OF BUSINESS DEVELOPMENT
CONTACT
BRICKBIO
OUR ADDRESS
12 Gill Street, Suite 4200
Woburn, MA, 01801, USA
For any general inquiries, please fill in the following contact form:
